



KLINIKUM
DER UNIVERSITÄT MÜNCHEN

MEDIZINISCHE KLINIK UND POLIKLINIK III
DIREKTOR: PROF. DR. DR. M. VON BERGWELT



Efficacy and safety of Rituximab, high-dose Ara-C and Dexamethasone (R-HAD) alone or in combination with bortezomib in patients with relapsed or refractory mantle cell lymphoma



MCL2005-01 (R-HAD); EudraCT-Nr.: 2005-005144-62; ClinicalTrials.gov Identifier: NCT01449344

Update March 28, 2019, PD Dr. Eva Hoster


Sponsor: University Hospital Munich, Department of Medicine III, on Behalf of the European MCL Network





Recruitment

Randomized





Randomization per study group

Group	R-HAD	R-HAD+B	Total
LYSA	26	24	50
GLSG	38	40	78
Total	64	64	128

